Yue Tan

A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL

Wei Cheng, Jianfeng Zhou, H. Cai, 2021, Blood Cancer Journal.

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

Xiaoming Feng, B. Deng, Jing Pan, 2020, Journal of cellular and molecular medicine.

Novel full-human CD22-CAR therapy overcomes resistance to previous CD19/22-CAR regimens in ALL

Yue Tan, 2021 .

Tim-3: An inhibitory immune checkpoint is associated with maternal-fetal tolerance and recurrent spontaneous abortion.

Fuyan Wang, Wuan Zhu, Yue Tan, 2022, Clinical immunology.

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Ying Yuan, Fangrong Yan, Jiecheng Zhang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL

Xiaoming Feng, B. Deng, Jing Pan, 2021, Cancer Immunology, Immunotherapy.

Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children

Q. Zheng, Xiaoming Feng, B. Deng, 2020, Leukemia.

Clinical advancement of precision theranostics in prostate cancer

Kai Liu, Hong Zhao, Yongxiang Tang, 2023, Frontiers in Oncology.

Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

B. Deng, Jing Pan, Zhuojun Ling, 2022, Blood.

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Jiecheng Zhang, Xiaoming Feng, Lingling Shan, 2023, Journal of Hematology & Oncology.

Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.

Xiaoming Feng, B. Deng, Jing Pan, 2023, The Lancet. Oncology.